Public Drug Program Formulary Tables – Psoriasis and Psoriatic Arthritis
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
|---|---|---|---|---|---|---|---|---|
| Alberta | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00045017.PDF | https://pdf.hres.ca/dpd_pm/00066773.PDF | July 21, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | https://pdf.hres.ca/dpd_pm/00068228.PDF | Nov 14, 2022 | |
| Alberta | Biologics and Biosimilars | Adalimumab | Amgevita® | No | No | NA | https://pdf.hres.ca/dpd_pm/00067468.PDF | 9 September, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068763.PDF | Dec 14, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068848.PDF | December 22, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Humira® | No | No | https://pdf.hres.ca/dpd_pm/00052133.PDF | https://pdf.hres.ca/dpd_pm/00068848.PDF | December 22, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00067757.PDF | October 11, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00058541.PDF | October 30, 2020 |
| Alberta | Biologics and Biosimilars | Adalimumab | SIMLANDI™ | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068814.PDF | Dec 9, 2022 |
| Alberta | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00069429.PDF | February 3, 2023 |
| Alberta | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | https://pdf.hres.ca/dpd_pm/00064702.PDF | https://pdf.hres.ca/dpd_pm/00064702.PDF | February 14, 2022 |
| Alberta | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | https://pdf.hres.ca/dpd_pm/00044076.PDF | https://pdf.hres.ca/dpd_pm/00051682.PDF | June 7, 2019 |
| Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00049574.PDF | https://pdf.hres.ca/dpd_pm/00053920.PDF | November 13, 2019 |
| Alberta | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | NA | https://pdf.hres.ca/dpd_pm/00065129.PDF | March 17, 2022 |
| Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | Yes - pediatric patients weighing less than 63 kg | No | https://pdf.hres.ca/dpd_pm/00048003.PDF | https://pdf.hres.ca/dpd_pm/00060454.PDF | March 19, 2021 |
| Alberta | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00049267.PDF | https://pdf.hres.ca/dpd_pm/00069556.PDF | Jan 18, 2023 |
| Alberta | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00051840.PDF | https://pdf.hres.ca/dpd_pm/00067454.PDF | September 9, 2022 |
| Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | https://pdf.hres.ca/dpd_pm/00057930.PDF | https://pdf.hres.ca/dpd_pm/00068091.PDF | November 8, 2022 |
| Alberta | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A | NA | https://pdf.hres.ca/dpd_pm/00065940.PDF | May 17, 2022 |
| Alberta | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | https://pdf.hres.ca/dpd_pm/00059824.PDF | ||
| Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00047753.PDF | https://pdf.hres.ca/dpd_pm/00067676.PDF | Oct 07, 2022 |
| Alberta | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00050544.PDF | https://pdf.hres.ca/dpd_pm/00069528.PDF | Feb 09, 2023 |
| Alberta | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00047053.PDF | https://pdf.hres.ca/dpd_pm/00057004.PDF | |
| Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00069828.PDF | ||
| Alberta | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | https://pdf.hres.ca/dpd_pm/00068865.PDF | ||
| Alberta | Biologics and Biosimilars | Risankizumab | Skyrizi® | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00069300.PDF | ||
| Alberta | Biologics and Biosimilars | Sécukinumab | Cosentyxᴹᴰ | Yes - S/A | Yes - S/A | https://pdf.hres.ca/dpd_pm/00067634.PDF | ||
| Alberta | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - SA | N/A | https://pdf.hres.ca/dpd_pm/00060995.PDF | https://pdf.hres.ca/dpd_pm/00064464.PDF | January 24, 2022 |
| Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00048246.PDF | https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/stelara_cpm.pdf | January 5, 2023 |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034146.PDF | https://pdf.hres.ca/dpd_pm/00055197.PDF | February 25, 2020 |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | https://pdf.hres.ca/dpd_pm/00034364.PDF | https://pdf.hres.ca/dpd_pm/00034364.PDF | April 4, 2016 |
| Alberta | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | https://pdf.hres.ca/dpd_pm/00036393.PDF | https://pdf.hres.ca/dpd_pm/00065877.PDF | May 12, 2022 |
| Alberta | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes - SA | N/A | https://pdf.hres.ca/dpd_pm/00056991.PDF | https://pdf.hres.ca/dpd_pm/00066402.PDF | June 17, 2022 |
| Alberta | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | NA | https://pdf.hres.ca/dpd_pm/00060714.PDF | April 13, 2021 |
| Alberta | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes | N/A | https://pdf.hres.ca/dpd_pm/00031077.PDF | https://pdf.hres.ca/dpd_pm/00031077.PDF | June 29, 2015 |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues (Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | NA | https://pdf.hres.ca/dpd_pm/00064010.PDF | December 13, 2021 |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues (Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | https://pdf.hres.ca/dpd_pm/00041695.PDF | https://pdf.hres.ca/dpd_pm/00041695.PDF | October 17, 2017 |
| Alberta | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | https://pdf.hres.ca/dpd_pm/00046848.PDF | https://pdf.hres.ca/dpd_pm/00046848.PDF | August 10, 2018 |
| Alberta | Systemic Drugs | Apremilast | Otezla® | No | No | https://pdf.hres.ca/dpd_pm/00041998.PDF | https://pdf.hres.ca/dpd_pm/00057499.PDF | August 5, 2020 |
| Alberta | Systemic Drugs | Celecoxib | No | No | https://pdf.hres.ca/dpd_pm/00065005.PDF | March 10, 2022 | ||
| Alberta | Systemic Drugs | Cyclosporine | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00029804.PDF | March 13, 2015 | ||
| Alberta | Systemic Drugs | Leflunomide | Arava® | N/A | No | |||
| Alberta | Systemic Drugs | Methotrexate | Methotrexate | Yes | Yes | |||
| Alberta | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Alberta | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | Under review | https://pdf.hres.ca/dpd_pm/00051987.PDF | https://pdf.hres.ca/dpd_pm/00065725.PDF | May 09, 2022 |
| Alberta | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068075.PDF | Aug 02, 2022 |
| British Columbia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00064702.PDF | ||
| British Columbia | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | |||
| British Columbia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | N/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Etanercept | Enbrel® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
| British Columbia | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Remsima® | No | No | |||
| British Columbia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
| British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
| British Columbia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | |||
| British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A | |||
| British Columbia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | No | N/A | |||
| British Columbia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A | |||
| British Columbia | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | No | N/A | |||
| British Columbia | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes | N/A | Tazorac Cream (tazarotene): https://pdf.hres.ca/dpd_pm/00033182.PDF | https://pdf.hres.ca/dpd_pm/00033182.PDF | December 8, 2015 |
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| British Columbia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| British Columbia | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| British Columbia | Systemic Drugs | Celecoxib | No | Yes – S/A | ||||
| British Columbia | Systemic Drugs | Cyclosporine | Yes – S/A | N/A | ||||
| British Columbia | Systemic Drugs | Leflunomide | Arava® | No | Yes - S/A | |||
| British Columbia | Systemic Drugs | Methotrexate | Methotrexate | Yes | Yes | |||
| British Columbia | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| British Columbia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| British Columbia | Systemic Drugs | Upadacitinib | Rinvoq | N/A | No | |||
| Manitoba | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | No | No | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - EDS | N/A | |||
| Manitoba | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
| Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis. | |||
| Manitoba | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Avsola® | Yes - EDS | Yes - EDS | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Remsima® | No | No | |||
| Manitoba | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
| Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS | |||
| Manitoba | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - EDS | N/A | |||
| Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | No | |||
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Manitoba | Systemic Drugs | Acitretin | Soriatane | Yes | N/A | |||
| Manitoba | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| Manitoba | Systemic Drugs | Celecoxib | N/A | Yes | https://pdf.hres.ca/dpd_pm/00044180.PDF | https://pdf.hres.ca/dpd_pm/00067016.PDF | August 4, 2022 | |
| Manitoba | Systemic Drugs | Cyclosporine | N/A | Yes - EDS | ||||
| Manitoba | Systemic Drugs | Leflunomide | Arava® | No | Yes – EDS | |||
| Manitoba | Systemic Drugs | Methotrexate | Yes | Yes | https://pdf.hres.ca/dpd_pm/00042486.PDF | https://pdf.hres.ca/dpd_pm/00053187.PDF | September 12, 2019 | |
| Manitoba | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Manitoba | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Manitoba | Systemic Drugs | Upadacitinib | Rinvoq | N/A | No | |||
| Manitoba | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | ||||
| New Brunswick | Biologics and Biosimilars | Abatacept | Orencia® | No | No | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Abrilada® | No | No | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | SIMLANDI | No | No | |||
| New Brunswick | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - S/A | No | |||
| New Brunswick | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | ||||
| New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes – S/A | ||||
| New Brunswick | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. | |||
| New Brunswick | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
| New Brunswick | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
| New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Remsima® | Non | Non | |||
| New Brunswick | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
| New Brunswick | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
| New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
| New Brunswick | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - S/A | N/A | |||
| New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| New Brunswick | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| New Brunswick | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| New Brunswick | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes – S/A | N/A | |||
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | Yes | N/A | |||
| New Brunswick | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| New Brunswick | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| New Brunswick | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| New Brunswick | Systemic Drugs | Cyclosporine | Yes | Yes | ||||
| New Brunswick | Systemic Drugs | Leflunomide | Arava® | N/A | Yes | |||
| New Brunswick | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| New Brunswick | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| New Brunswick | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | Yes - S/A | |||
| New Brunswick | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - S/A | |||
| New Brunswick | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | ||||
| Newfoundland and Labrador | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - S/A | Yes - SA | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - SA | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | N/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Brenzys® | No | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only. | Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only. | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - SA | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A; : Inflectra, Renflexis or Avsola are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – S/A | N/A | |||
| Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – S/A | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | No | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes - S/A | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes – S/A | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Newfoundland and Labrador | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Newfoundland and Labrador | Systemic Drugs | Apremilast | Otezla® | No | s.o. | |||
| Newfoundland and Labrador | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Newfoundland and Labrador | Systemic Drugs | Cyclosporine | Yes | N/A | ||||
| Newfoundland and Labrador | Systemic Drugs | Leflunomide | Arava® | N/A | Yes | |||
| Newfoundland and Labrador | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Newfoundland and Labrador | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Newfoundland and Labrador | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Newfoundland and Labrador | Systemic Drugs | Upadacitinib | Rinvoq | Yes- S/A | N/A | |||
| Newfoundland and Labrador | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | No | N/A | ||||
| NIHB | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
| NIHB | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
| NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
| NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
| NIHB | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
| NIHB | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
| NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| NIHB | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
| NIHB | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| NIHB | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
| NIHB | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
| NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
| NIHB | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
| NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Tazarotene(topical retinoids) | Tazorac | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| NIHB | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| NIHB | Systemic Drugs | Apremilast | Otezla® | No | N/A | |||
| NIHB | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| NIHB | Systemic Drugs | Cyclosporine | Cyclosporine | Yes | N/A | https://pdf.hres.ca/dpd_pm/00029804.PDF | NA | March 13, 2015 |
| NIHB | Systemic Drugs | Leflunomide | Arava® | Yes | Yes | |||
| NIHB | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| NIHB | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| NIHB | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| NIHB | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - SA | |||
| Northwest Territories | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
| Northwest Territories | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
| Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
| Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
| Northwest Territories | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
| Northwest Territories | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
| Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
| Northwest Territories | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Northwest Territories | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
| Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
| Northwest Territories | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
| Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Northwest Territories | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Northwest Territories | Systemic Drugs | Apremilast | Otezla® | No | N/A | |||
| Northwest Territories | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Northwest Territories | Systemic Drugs | Cyclosporine | Yes | N/A | ||||
| Northwest Territories | Systemic Drugs | Leflunomide | Arava® | Yes | Yes | |||
| Northwest Territories | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Northwest Territories | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Northwest Territories | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Northwest Territories | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - SA | |||
| Nova Scotia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | No - barring exception | No - barring exception | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | s.o. | |||
| Nova Scotia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
| Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | No - barring exception | No - barring exception | |||
| Nova Scotia | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - EDS | Yes – EDS | |||
| Nova Scotia | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS | |||
| Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Avsola® | Yes – EDS | Yes – EDS | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | No - barring exception | No - barring exception | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes - EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Nova Scotia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
| Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes - EDS | |||
| Nova Scotia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – EDS | N/A | |||
| Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes - EDS | No | |||
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes – EDS | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes – EDS | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes – EDS | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes – EDS | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes - EDS | N/A | |||
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | Yes | N/A | |||
| Nova Scotia | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Nova Scotia | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| Nova Scotia | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Nova Scotia | Systemic Drugs | Cyclosporine | Yes | N/A | ||||
| Nova Scotia | Systemic Drugs | Leflunomide | Arava® | N/A | Yes | |||
| Nova Scotia | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Nova Scotia | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Nova Scotia | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Nova Scotia | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - EDS | |||
| Nunavut | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
| Nunavut | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
| Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
| Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
| Nunavut | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
| Nunavut | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
| Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Nunavut | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
| Nunavut | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
| Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
| Nunavut | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
| Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Tazarotene(topical retinoids) | Tazorac | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Nunavut | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Nunavut | Systemic Drugs | Apremilast | Otezla® | No | N/A | |||
| Nunavut | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Nunavut | Systemic Drugs | Cyclosporine | Cyclosporine | Yes | N/A | |||
| Nunavut | Systemic Drugs | Leflunomide | Arava® | Yes | Yes | |||
| Nunavut | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Nunavut | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Nunavut | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Nunavut | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - SA | |||
| Ontario | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | NA | https://pdf.hres.ca/dpd_pm/00068228.PDF | Nov 14, 2022 |
| Ontario | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U | No | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
| Ontario | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes- L/U | N/A | |||
| Ontario | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
| Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | No | |||
| Ontario | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U | Yes – L/U | |||
| Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – L/U | No | |||
| Ontario | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – L/U | Yes – L/U | |||
| Ontario | Biologics and Biosimilars | Golimumab | Simponi® | N/A | No | |||
| Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Ontario | Biologics and Biosimilars | Infliximab | Avsola® | Yes – L/U | Yes – L/U | |||
| Ontario | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – L/U | Yes – L/U | |||
| Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No | No | |||
| Ontario | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – L/U | Yes – L/U | |||
| Ontario | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | No | |||
| Ontario | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Ontario | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
| Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | No | |||
| Ontario | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – L/U | N/A | |||
| Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | No | N/A | |||
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | Yes – L/U | N/A | |||
| Ontario | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Ontario | Systemic Drugs | Apremilast | Otezla® | Yes - L/U | Yes - L/U | |||
| Ontario | Systemic Drugs | Celecoxib | N/A | No | ||||
| Ontario | Systemic Drugs | Cyclosporine | Yes | N/A | ||||
| Ontario | Systemic Drugs | Leflunomide | Arava® | N/A | Yes | |||
| Ontario | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Ontario | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Ontario | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Ontario | Systemic Drugs | Upadacitinib | Rinvoq | N/A | No | |||
| Prince Edward Island | Biologics and Biosimilars | Abatacept | Orencia® | N/A | Yes - S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | |||
| Prince Edward Island | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes - S/A | N/A | |||
| Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes | |||
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes-S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Avsola® | No | No | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes - S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Prince Edward Island | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
| Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
| Prince Edward Island | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes-S/A | N/A | |||
| Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes-S/A | No | |||
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes – S/A | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes - S/A | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Tazarotene (topical retinoids) | No | N/A | ||||
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes – S/A | N/A | |||
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | Yes | N/A | |||
| Prince Edward Island | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Prince Edward Island | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| Prince Edward Island | Systemic Drugs | Celecoxib | N/A | No | ||||
| Prince Edward Island | Systemic Drugs | Cyclosporine | Yes | N/A | ||||
| Prince Edward Island | Systemic Drugs | Leflunomide | Arava® | N/A | Yes – S/A | |||
| Prince Edward Island | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Prince Edward Island | Systemic Drugs | Sulfasalazine | N/A | Yes – S/A | ||||
| Prince Edward Island | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Prince Edward Island | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Abatacept | Orencia® | N/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A. If treatment and reimbursement began before March 3 2021. | Yes - S/A. If treatment and reimbursement began before March 3 2021. | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | |||
| Quebec | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | |||
| Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A. If treatment and reimbursement began before August 19 2020. | Yes – S/A. If treatment and reimbursement began before August 19 2020. | |||
| Quebec | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Quebec | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A. If treatment and reimburesement began before August 19, 2020 | Yes – S/A. If treatment and reimburesment began before August 19, 2020 | |||
| Quebec | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A | |||
| Quebec | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
| Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | |||
| Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | Yes – S/A | |||
| Quebec | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Quebec | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Quebec | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A | |||
| Quebec | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Oui | N/A | |||
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | Yes | N/A | |||
| Quebec | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Quebec | Systemic Drugs | Apremilast | Otezla® | Yes – S/A | Yes – S/A | |||
| Quebec | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Quebec | Systemic Drugs | Cyclosporine | Yes | |||||
| Quebec | Systemic Drugs | Leflunomide | Arava® | N/A | Yes | |||
| Quebec | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Quebec | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Quebec | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | Yes - S/A | |||
| Quebec | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - S/A | |||
| Quebec | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | ||||
| Saskatchewan | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | No | No | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
| Saskatchewan | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
| Saskatchewan | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes – EDS | N/A | |||
| Saskatchewan | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
| Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation | No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation | |||
| Saskatchewan | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Avsola® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | No | No | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Saskatchewan | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
| Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – EDS | N/A | |||
| Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | Yes – EDS | |||
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Tazarotene (topical retinoids) | Tazorac | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Saskatchewan | Systemic Drugs | Acitretin | Soriatane® | Yes – EDS | N/A | |||
| Saskatchewan | Systemic Drugs | Apremilast | Otezla® | No | No | |||
| Saskatchewan | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Saskatchewan | Systemic Drugs | Cyclosporine | Yes – EDS | N/A | ||||
| Saskatchewan | Systemic Drugs | Leflunomide | Arava® | N/A | Yes – EDS | |||
| Saskatchewan | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Saskatchewan | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Saskatchewan | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | Yes - EDS | |||
| Saskatchewan | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - EDS | |||
| Yukon | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
| Yukon | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
| Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
| Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
| Yukon | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
| Yukon | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
| Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
| Yukon | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
| Yukon | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
| Yukon | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
| Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
| Yukon | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
| Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
| Yukon | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
| Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Gel | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Dovobet®_Ointment | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Combination Vitamin D3 Analogues and Corticosteroids | Enstilar™_Foam | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Halobetasol Propionate Lotion 0.01% | BRYHALI🅪 | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Tazarotene(topical retinoids) | Tazorac | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Dovonex® (calcipotriol) | Yes | N/A | |||
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Silkis (calcitriol ) | No | N/A | |||
| Yukon | Systemic Drugs | Acitretin | Soriatane® | Yes | N/A | |||
| Yukon | Systemic Drugs | Apremilast | Otezla® | No | N/A | |||
| Yukon | Systemic Drugs | Celecoxib | N/A | Yes | ||||
| Yukon | Systemic Drugs | Cyclosporine | Cyclosporine | Yes | N/A | |||
| Yukon | Systemic Drugs | Leflunomide | Arava® | Yes | Yes | |||
| Yukon | Systemic Drugs | Methotrexate | Yes | Yes | ||||
| Yukon | Systemic Drugs | Sulfasalazine | N/A | Yes | ||||
| Yukon | Systemic Drugs | Tofacitinib | Xeljanz® | N/A | No | |||
| Yukon | Systemic Drugs | Upadacitinib | Rinvoq | N/A | Yes - SA |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.